The following is a summary of "Transit time flow management as a management strategy in high-risk groups undergoing coronary ...

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today they have entered a non-binding Memorandum of ...

An investigational monoclonal antibody called bentracimab can safely and effectively reverse potentially catastrophic ...

Q4 2024 Earnings Call Transcript March 31, 2025 Cytosorbents Corporation beats earnings expectations. Reported EPS is $-0.03, ...

Connie Bowling, a 75-year-old deaf patient from Forsyth County, received a left ventricular assist device (LVAD) in March ...

Phillip Chan; Chief Executive Officer, Director; Cytosorbents Corp. Peter Mariani; Chief Financial Officer; Cyt ...

While the typical image of someone suffering a heart attack might be a man clutching his chest, heart disease is a major problem for women, too. In ...

In sharp contrast to earlier studies, patients with severe triple-vessel heart disease fared equally well whether they ...

Patients with narrowing of at least 50% in three major coronary arteries did equally well when treated with a minimally ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Marc Humbert, M.D., Ph.D., professor of respiratory medicine at Université Paris-Saclay and Inserm, believes that recent ...